VivoSeq
Neurology

Developmental and Epileptic Encephalopathy

7

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Developmental and Epileptic Encephalopathy is an early-stage landscape with 7 programs across 6 companies. The most active players are Neurocrine Biosciences, Institut de Recherches Internationales Servier, Praxis Precision Medicines. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

33/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 2Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

1 program

Phase 2P

Praxis Precision Medicines

1 program

Phase 2X

Xenon Pharmaceuticals Inc.

1 program

Phase 3L

Longboard Pharmaceuticals

2 programs

Phase 3Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Terminated2 · 33%
Recruiting2 · 33%
Enrolling by invitation1 · 17%
Completed1 · 17%

Clinical Trials

Trial Activity

6 trials

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
Recruiting·PPraxis Precision Medicines·Phase 1/2·NCT05737784·60 enrolled
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
Recruiting·Institut de Recherches Internationales Servier logoInstitut de Recherches Internationales Servier·Phase 1/2·NCT07227857·20 enrolled
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Enrolling by invitation·LLongboard Pharmaceuticals·Phase 3·NCT06908226·324 enrolled
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Completed·LLongboard Pharmaceuticals·Phase 2·NCT05626634·41 enrolled
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Terminated·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 2·NCT04873869·8 enrolled
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Terminated·XXenon Pharmaceuticals Inc.·Phase 3·NCT04639310·8 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)